New Study Demonstrates Patients With High-Risk MammaPrint Profile Benefit From Chemotherapy

HUNTINGTON BEACH, California, and AMSTERDAM, April 29, 2010 - Today, at the 11th Annual Meeting of the American Society of Breast
Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced
that Breast Cancer Research and Treatment has published an important study
demonstrating the benefit of adjuvant chemotherapy for patients with a
high-risk of breast cancer recurrence according to the MammaPrint test. The
ASBS meeting takes places April 28 - May 2, 2010, at the Bellagio in Las
Vegas, where you can meet the Agendia team at booth # 314.

The study evaluated 541 patients who were classified as either high-risk
or low-risk for breast cancer recurrence using the 70-gene MammaPrint
signature. For patients classified as high-risk, the addition of chemotherapy
to hormone treatment showed significant survival benefit and meaningful
clinical benefit. This benefit was not significant in low-risk patients, who
were at such reduced risk for recurrence and cancer-related death, that
adding chemotherapy did not appear to be clinically meaningful.

"It is important to provide patients with individualized treatment
regimens. These findings help further this aim and confirm MammaPrint's
predictive capabilities in determining which patients are likely to benefit
from chemotherapy," commented Richard Bender, MD, FACP, Chief Medical Officer
of Agendia and study co-author.

The study titled, "The predictive value of the 70-gene signature for
adjuvant chemotherapy in early breast cancer," can be accessed at
www.springer.com/medicine/oncology/journal/10549.

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test cleared by
the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro
diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and
analytical validation and reporting systems to ensure patient safety issues
are addressed. Highly accurate, MammaPrint identifies patients with early
metastasis risk - patients who are likely to develop metastases within five
years following surgery. Several authoritative studies have shown that
chemotherapy particularly reduces early metastasis risk. In planning
treatment, the MammaPrint test results provide doctors with a clear rationale
to assess the benefit of chemotherapy in addition to other clinical
information and pathology tests.

All MammaPrint tests are conducted in Agendia's CAP-accredited and CLIA
compliant service laboratories. Breast cancer recurrence assays currently
marketed by other manufacturers have not been subject to the rigorous FDA
clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution,
striving to bring more effective, individualized treatments within reach of
patients. Building on a cutting-edge genomics platform for tumor gene
expression profiling, the company's tests help physicians more accurately
tailor cancer treatments. Agendia markets four products, with several new
genomic tests under development. In addition, Agendia collaborates with
pharmaceutical companies to develop highly effective personalized drugs in
the area of oncology. Agendia is based in Huntington Beach, California, and
in Amsterdam, The Netherlands.

MEDIA CONTACTS: Hans Herklots, Head of Corporate Communications, Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile, hans.herklots at agendia.com; Valerie Delva, Account Executive, Ricochet Public Relations, +1-212-679-3300 x131 Office, vdelva at ricochetpr.com